(Q62105390)
Statements
A Phase II Randomized, Double-Blinded, Placebo-Controlled, Multi-Center Study of Subcutaneous Daclizumab in Patients With Active, Relapsing Forms of Multiple Sclerosis (English)
0 references
April 2005
0 references
270
0 references
18 year
0 references
55 year
0 references